Evkeeza®

Understanding Evkeeza® 

Evkeeza® (evinacumab-dgnb) is a monoclonal antibody used to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic condition characterized by extremely high cholesterol levels from birth.

In HoFH, mutations in both copies of the LDLR gene impair the body’s ability to remove low-density lipoprotein cholesterol (LDL-C) from the bloodstream, leading to severe, early-onset cardiovascular disease.

Evkeeza® provides a novel treatment option for patients with HoFH who often do not respond adequately to traditional cholesterol-lowering therapies like statins.

How Evkeeza® Works:

• Reduces LDL-C levels significantly
• Improves overall lipid control
• Helps manage the high cardiovascular risk associated with HoFH

FDA Approval:

• Evkeeza® (evinacumab-dgnb): Approved in 2021

For more information, please visit the Evkeeza® patient website and speak with your healthcare provider to determine if Evkeeza® is the right treatment option for you.